KALVISTA PHARMACEUTICALS, INC.
55 Cambridge Parkway
Suite 901E
Cambridge, Massachusetts 02142
May 27, 2021
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
| Attention: | Ada D. Sarmento | |
| Re: | KalVista Pharmaceuticals, Inc. Registration Statement on Form S-3 (File No. 333-256378) filed May 21, 2021. | |
Requested Date: June 1, 2021
Requested Time: 4:30 PM Eastern Time
Ladies and Gentlemen:
KalVista Pharmaceuticals, Inc. (the “Registrant”) hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to declare the above-captioned Registration Statement on Form S-3 effective at the “Requested Date” and “Requested Time” set forth above or as soon thereafter as practicable, or at such later time as the Registrant may orally request via telephone call to the staff of the Commission.
The Registrant hereby authorizes Robert A. Freedman or Julia Forbess, both of whom are attorneys with the Registrant’s outside legal counsel, Fenwick & West LLP, to orally modify or withdraw this request for acceleration.
The Registrant requests that it be notified of such effectiveness by a telephone call to Mr. Freedman at (650) 335-7292 or, in his absence, to Ms. Forbess at (415) 875-2420.
[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]
Sincerely,
KalVista Pharmaceuticals, Inc. | ||
| By: | /s/ Benjamin L. Palleiko | |
Benjamin L. Palleiko Chief Financial Officer and Chief Business Officer | ||
| cc: | Thomas Andrew Crockett, Chief Executive Officer |
KalVista Pharmaceuticals, Inc.
Robert A. Freedman, Esq.
Julia Forbess, Esq.
Michael Pilo, Esq.
Fenwick & West LLP
